CAN 296Alternative Names: CAN-296
Latest Information Update: 19 Mar 2007
At a glance
- Originator GlycoGenesys
- Class Antifungals
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Mycoses
Most Recent Events
- 27 Aug 2003 This compound is still in active development
- 17 May 2001 This compound is still in active development
- 21 May 1999 SafeScience has been awarded a US patent covering the use of CAN 296 and analogues in the treatment of fungal disease in animals and humans